Clinical trials
Chronic Heart Failure With Reduced Ejection Fraction clinical trials
Below are recruiting chronic heart failure with reduced ejection fraction clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05651919Recruiting
Blood test study to understand diabetic heart weakness
This study measures immune cells from your blood to find markers (biomarkers) that may explain or predict diabetic cardiomyopathy, a type of heart condition linked to diabetes. You may benefit mainly by being closely monitored and contributing to research that could improve future diagnosis or risk tracking.
BronAges 40–85 - NCT05255172Enrolling by invitation
Exercise program for heart failure with preserved or reduced pumping
This trial tests whether a structured exercise program can help people with heart failure. It focuses on people who are currently not very active, aiming to improve symptoms and heart/fitness measures safely.
LundAges 50–90 - NCT05138575RecruitingPhase 2
Testing SGLT2 pill and potassium nitrate for heart failure with preserved EF
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04913805RecruitingPhase 2
Study for HFpEF using heart pressure and energy signals
This Phase 2 study tests how matching heart “filling pressure” and heart muscle “energy use” may improve understanding or treatment of HFpEF, a type of heart failure with preserved pumping strength. You may be asked to have heart scans/tests and follow a study plan if your symptoms and test results fit.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04592445Recruiting
Nerve ablation for right-sided symptoms in HFpEF heart failure
This trial tests a procedure to “turn off” the right greater splanchnic nerve to improve symptoms in people with HFpEF (heart failure with preserved pumping function). If successful, it may reduce shortness of breath and fluid congestion in daily life.
Birmingham, AlabamaAges 40 years+ - NCT07692256RecruitingPhase 2
Empagliflozin for heart failure in children
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
Cairo, Cairo GovernorateAges 1 month–18 years - NCT07552142Recruiting
Heart Failure Check-In: Using Questionnaires to Spot Early Warning Signs
This study asks heart failure patients who recently were hospitalized to answer regular questionnaires about how they're feeling. Researchers want to see if these questions can detect when heart failure is getting worse before a patient needs emergency care.
Moscow, Non-US/Non-CanadianAges 18 years+ - NCT07296081Recruiting
PET scan study for heart scarring in heart failure
This study uses a special PET scan to look for scarring (fibrosis) in the heart muscle of people with heart failure. It may help doctors better understand why some hearts get stiff or weak.
Coimbra, Coimbra DistrictAges 18 years+ - NCT07025629RecruitingPhase 3
Dapagliflozin after ICU discharge for heart and kidney health
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
ParisAges 18 years+ - NCT06916585RecruitingPhase 2
Testing AS1501 for acute-on-chronic liver failure
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
Shenzhen, GuangdongAges 18–75 - NCT07210606RecruitingPhase 4
Sleep apnea treatment study for veterans with heart failure
This study looks at how well a medicine called trazodone might help treat central sleep apnea in veterans who also have heart failure. It aims to improve sleep and breathing, which may help you feel better.
Detroit, MichiganAges 18 years+ - NCT05712824Recruiting
Device to measure left-heart pressure in advanced heart failure
This trial tests a wirelessly implanted device that measures pressure in the left upper heart chamber (left atrial pressure) in people with advanced heart failure. By tracking that pressure, researchers hope to better understand disease status and guide care.
Tbilisi, GeorgiaAges 22–88 - NCT06147336Recruiting
Testing the V-Lap system for heart failure monitoring
This trial tests a new device called V-Lap that is placed in the heart to monitor pressure. It may help doctors better manage heart failure and reduce hospital stays. Researchers want to see if it works well in people with mild to moderate heart failure.
Boston, MassachusettsAges 22–88 - NCT05876000Recruiting
Heart pump study for very severe heart failure
This trial tests a left ventricular assist system (a mechanical heart pump for the left side of the heart) in people with very severe heart failure. It may help people who are too sick or not improving despite best available medical treatment.
GrazAges 18–75 - NCT05672836RecruitingPhase 4
Enavogliflozin after TAVR for heart narrowing with mild heart weakness
This trial tests enavogliflozin (a diabetes medication that may help the heart) in people who have had a TAVR procedure for severe aortic stenosis. It looks at whether the medicine can improve outcomes for people with symptoms and mildly reduced or preserved pumping function.
Bucheon-siAges 19 years+ - NCT05230745Recruiting
Test device for heart failure safety and how well it works
This trial studies whether the ContraBand device can be safely placed in people with long-term, symptomatic heart failure and reduced heart pumping. It also looks at whether the approach is practical and tolerable, and gathers early safety information.
AalstAges 18–85 - NCT04323371Recruiting
Study testing for heart-shock to reduce future events
This trial studies how to identify different types of “cardiogenic shock,” a serious drop in heart blood flow. It aims to use detailed patient information to guide care and possibly lower the chance of dangerous outcomes.
MilanAges 18–74 - NCT05786417RecruitingPhase 4
Medication comparison for older adults with stable heart pain
This trial tests which heart medications work best for older adults who have stable angina (predictable chest pain) and multiple other long-term health problems. You may be asked to start or adjust medications and attend regular follow-up visits to see which approach controls symptoms and outcomes.
New Haven, ConnecticutAges 65 years+ - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT07434791Recruiting
Goal-directed therapy to protect kidneys and heart in diabetic kidney disease
This study tests whether a goal-directed treatment plan using several medications can lower the risk of kidney and heart problems for people with diabetes and kidney disease. It aims to help you manage your condition more effectively.
Toronto, OntarioAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+
Hear when a new Chronic Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic heart failure with reduced ejection fraction?
- Yes. Clin2 currently lists 93 recruiting chronic heart failure with reduced ejection fraction studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic heart failure with reduced ejection fraction trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic heart failure with reduced ejection fraction trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.